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The efficacy of autologous (ab) T-cell–based treatment strategies in chronic lympho-
cytic leukemia (CLL) has been modest. The Vg9Vd2-T cell subset consists of cytotoxic T
lymphocytes with potent antilymphoma activity via a major histocompatibility complex–
independent mechanism. We studied whether Vg9Vd2-T cells can be exploited as autol-
ogous effector lymphocytes in CLL. Healthy control Vg9Vd2-T cells were activated by and
had potent cytolytic activity against CLL cells. However, CLL-derived Vg9Vd2-T cells
proved dysfunctional with respect to effector cytokine production and degranulation,
despite an increased frequency of the effector-type subset. Consequently, cytotoxicity
against malignant B cells was hampered. A comparable dysfunctional phenotype was
observed in healthy Vg9Vd2-T cells after coculture with CLL cells, indicating a leukemia-
induced mechanism. Gene-expression profiling implicated alterations in synapse formation
as a conceivable contributor to compromised Vg9Vd2-T–cell function in CLL patients.
Dysfunction of Vg9Vd2-T cells was fully reversible upon activation with autologous
monocyte-derived dendritic cells (moDCs). moDC activation resulted in efficient expansion
and predominantly yielded Vg9Vd2-T cells with a memory phenotype. Furthermore,
ibrutinib treatment promoted an antitumor T helper 1 (TH1) phenotype in Vg9Vd2-T cells, andwedemonstrated binding
of ibrutinib to IL-2-inducible kinase (ITK) in Vg9Vd2-T cells. Taken together, CLL-mediated dysfunction of autologous
Vg9Vd2-T cells is fully reversible, resulting in potent cytotoxicity towardCLL cells. Our data support the potential use of
Vg9Vd2-T cells as effector T cells in CLL immunotherapy and favor further exploration of combining Vg9Vd2-T-cell–
based therapy with ibrutinib. (Blood. 2018;132(21):2260-2272)
Introduction
Although novel drugs that inhibit key kinases of the B-cell re-
ceptor (BCR) signaling pathway are valuable additions to the
therapeutic arsenal of chronic lymphocytic leukemia (CLL), these
agents are not curative; continuous treatment is required, which
invokes toxicities and resistance.1
Allogeneic hematopoietic stem cell therapy has demonstrated
that T-cell–based therapy has curative potential in CLL.2,3
However, current autologous T-cell–based approaches, such as
checkpoint inhibition and chimeric antigen receptor T cells, have
yielded limited response rates in CLL,4-8 specifically when
compared with their activity in more aggressive lymphoproli-
ferative diseases (eg, acute lymphocytic leukemia).9-11 Activation
of autologous T cells is constrained by low immunogenicity of
CLL cells and by acquired T-cell dysfunction that progresses
throughout the disease.12 T-cell abnormalities include altered
cytokine-secretion profiles, an exhausted phenotype, and
compromised cytotoxicity of CD81 T cells,13,14 in addition to a
subset distribution that is skewed toward an effector memory
phenotype, particularly in cytomegalovirus (CMV)1 patients.15
A total of 1% to 10% of CD31 T cells in the peripheral blood (PB)
carries a highly conserved gd T-cell receptor (TCR). Vg9Vd2-
T cells form the predominant gd T-cell subset in PB. In contrast to
ab T-cell antigen recognition, Vg9Vd2-T cells respond to stress
molecules in malignant cells, in a TCR-dependent, yet major
histocompatibility complex–independent, process.16,17 The Vg9Vd2-
TCR is activated via nonpeptidic phosphorylated antigens, or
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phosphoantigens, produced as intermediate metabolites in the
mevalonate pathwayduring cellular stress,malignant transformation,
or upon treatment with aminobisphosphonates.18,19 Upon activation,
Vg9Vd2-T cells have potent cytolytic activity against a wide variety
of malignant cells, including lymphoma cells.20-24 Moreover, strate-
gies based on Vg9Vd2-T cells, rather than total CD3 activation, have
low toxicity.24-30 Therefore, Vg9Vd2-T cells could represent an at-
tractive alternative source of autologous effector T cells for CLL
immunotherapy.20-24
In support of the relevance of Vg9Vd2-T cells in CLL, Coscia
et al have previously described a correlation between a
low proliferative response of Vg9Vd2-T cells to the aminobi-
sphosphonate zolendronate and short time to first treatment
status in CLL.31 Diminished proliferation was mostly seen in CLL
patients with unmutated immunoglobulin genes (U-CLL), who
had higher phosphoantigen levels and a hyperactive mevalo-
nate pathway in comparison with patients with CLL with mutated
immunoglobulin genes. The mechanism responsible for the
shorter time to first treatment and the ability of Vg9Vd2-T
cells from CLL patients to eradicate leukemic cells remain
unexplored. Moreover, little is known about functional charac-
teristics of this subset beyond proliferation and whether
perturbations demonstrated in ab T cells extend to Vg9Vd2-
T cells.
Therefore, we extensively characterized CLL-derived Vg9Vd2-




PB mononuclear cells (PBMCs) were isolated from PB samples
from untreated CLL patients or from age-matched healthy
controls (HCs) or fromHCbuffy coats from Sanquin Blood Supply
(Amsterdam, The Netherlands) and cryopreserved as described
previously (Table 1).32 The presence of monoclonal B-cell lym-
phocytosis was excluded in HCs by CD5, CD19, k, and l
immunophenotyping. The study was approved by the medical
ethics committee at the Academic Medical Center. Written in-
formed consent was obtained from all subjects in accordance
with the Declaration of Helsinki.
Flow cytometry
Thawed PBMCs were stained with monoclonal antibodies (de-
tails can be found in supplemental Methods and supplemental
Table 1, available on the Blood Web site) and measured on an
LSR Fortessa cytometer (BD Biosciences). Samples were ana-
lyzed with FlowJo for Mac v10.
Cytotoxicity
CD31TCR-Vg91TCR-Vd21 cells were sorted from PBMCs and
depleted of CD191 cells with magnetic beads (Miltenyi Biotec,
Bergisch Gladbach, Germany; CD19 fraction ,5%) on a FAC-
SAria IIu 3-laser (BD Biosciences). Thawed allogeneic CLL
PBMCs (.95% CD51CD191) or Daudi cells (American Type
Culture Collection) were used as target cells; they were labeled
with carboxyfluorescein succinimidyl ester (Thermo Fisher Sci-
entific, Waltham, MA) and subsequently treated with 25 mM
aminobisphosphonates (ABPs) for 2 hours (pamidronate; TEVA
Pharmachemie, Haarlem, The Netherlands) as indicated before
coculture with sorted Vg9Vd2-T cells (purity . 95%). Where in-
dicated, Vg9Vd2-T cells were treated with 100 nM concanamycin
A (Sigma-Aldrich, St. Louis, MO) or dimethyl sulfoxide control
for 2 hours and washed before coculture.
Viability was measured using MitoTracker Orange (Invitrogen)
and TO-PRO-3 (Invitrogen) on a FACSCanto flow cytometer
system (BD Biosciences).
Cytokine and degranulation assays
Target cells, thawed allogeneic CLL PBMCs (CD51CD191 . 95%)
or Daudi cells, were pretreated with 25 mM ABPs or medium
for 2 hours. CD19-depleted PBMCs were stimulated with
target cells at a 1:5 Vg9Vd2-T–cell effector-to-target cell ratio
with anti-CD28 (2 mg/mL, 15E8; Sanquin) for 16 to 18 hours or
with phorbol-12-myristate-13-acetate (PMA; 10 ng/mL; Sigma-
Aldrich) and ionomycin (1 mg/mL; Sigma-Aldrich) for 4 hours at
37°C. Brefeldin A (10 mg/mL; Invitrogen), GolgiStop, and anti-
CD107a allophycocyanin (BD Biosciences) were present during
the final 4 to 6 hours.33,34
Where indicated, CD19-depleted PBMCs were treated with
ibrutinib (Pharmacyclics, Sunnyvale, CA) or CC-292 (Selleckchem,
Houston, TX) for 30 minutes before coculture.
Coculture assay
CLL or healthy B cells were isolated with anti-CD19 magnetic
MicroBeads and cocultured with allogeneic CD19-depleted HC
PBMCs for 36 hours in a 1:10 ratio. CD25 expression was
measured, and cells were cocultured with ABP-pretreated Daudi
cells or stimulated with PMA/ionomycin for cytokine and de-
granulation assays, as above.
moDC-based ex vivo Vg9Vd2-T–cell activation
and expansion
CD31TCR-Vg91TCR-Vd21 cells were sorted using fluorescence-
activated cell sorting (FACS), as above, and cultured with
monocyte-derived dendritic cells (moDCs), as previously de-
scribed.35 In short, CD141 cells were isolated from HC or CLL
PBMCs (anti-CD14 magnetic MicroBeads; Miltenyi Biotec)
and cultured for 7 days in the presence of IL-4 (20 ng/mL;
R&D Systems, Minneapolis, MN) and granulocyte-macrophage
colony-stimulating factor (100 U/mL; Genzyme, Cambridge,
MA) (0.453 106 cells permilliliter) to generate immaturemoDCs.
These immature moDCs were matured with lipopolysaccharide
(100 ng/mL; Sigma-Aldrich) for 48 hours and ABPs (100 mM)
during the final 2 hours. Mature moDCs were then irradiated
(5000 rad) and cocultured with sorted Vg9Vd2-T cells in the
presence of IL-7 (10 U/mL) and IL-15 (10 ng/mL, R&D Systems)
for 2 weeks (1 3 106 Vg9Vd2-T cells and 0.2 3 106 moDCs per
milliliter). Vg9Vd2-T cells were restimulated with irradiated
moDCs weekly. When using autologous moDCs, cultures were
performed in medium supplemented with 10% autologous filter-
sterilized serum.
Vg9Vd2-T–cell generation from ABP/IL-
2–treated PBMCs
CD19-depleted PBMCs were treated with ABPs (25 mM) and IL-2
(1000 IU/mL; PeproTech, Rocky Hill, NJ) for 2 weeks. The
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medium was refreshed with ABPs and IL-2–containing medium
3 times per week.
RNA sequencing and data analysis
RNA was isolated (NucleoSpin RNA kit; Macherey Nagel, Düren,
Germany) from FACS-sorted CD31TCR-Vg91TCR-Vd21 cells.
Complementary DNA synthesis and amplification were per-
formed with the Ovation RNA-Seq System V2, followed by li-
brary preparation with the Ovation Ultralow System V2 (both
from Nugen, San Carlos, CA). Single-end 75–base pair se-
quencing was performed on an Illumina NextSeq 500 sequencer
by GenomeScan (Leiden, The Netherlands).
RNA sequencing analyses were performed using R (v.3.4.3) and
Bioconductor (v3.6) (see supplemental Methods). Gene set
enrichment analysis was performed using CAMERA, with a
combination of all Hallmark (collection H) and BioCarta (col-
lection C2) gene sets retrieved from the Molecular Signatures
Database (MSigDB v6.1; Entrez Gene ID version) and 10 man-
ually generated (supplemental Table 2) gene sets. Sequence
data have been deposited in the European Genome-phenome
Archive under accession number EGAS00001003193.
Ibrutinib pull-down
Biotinylated ibrutinib derivative (1 mM)36 was coupled to avidin
agarose (Thermo Fisher Scientific; 30 minutes at room tem-
perature). Remaining binding sites were blocked with 10 mM
biotin (Sigma-Aldrich; 15 minutes at room temperature). HC
Vg9Vd2-T cells or Mec-1 (DSMZ) cells were lysed with NP-40 lysis
buffer. Lysates were treated with 1 mM ibrutinib or 1 mMCC-292
(30 minutes at room temperature) and incubated overnight with
ibrutinib-coupled or uncoupled control agarose at 4°C. Proteins
were eluted by heating to 95°C in Laemmli buffer (60 mM Tris-
HCl pH 6.8, 10% glycerol, 2% sodium dodecyl sulfate, 100 mM
dithiothreitol) for 10 minutes and analyzed by western blotting,
as described previously.37 Blots were probed with anti-human
Bruton tyrosine kinase (BTK) (611116, BD Biosciences) or IL-2–
inducible T-cell kinase (ITK; 2380S; Cell Signaling Technology,
Danvers, MA).
Statistical analysis
Data were checked for normality with the D’Agostino-Pearson nor-
mality test and analyzed using 2-sided paired or unpaired t tests, the
Mann-Whitney U test, or 1-way analysis of variance (ANOVA; fol-
lowed by the Bonferroni or Dunnett post hoc test) as indicated, with
significance set at P , .05, using GraphPad Prism 5. Statistical
analyses of RNA sequencing data were performed using edgeR and
limma R/Bioconductor packages (supplemental Methods). Data are
presented as mean and standard error of the mean (SEM).
Results
Vg9Vd2-T cells are cytotoxic against CLL cells, yet
cytotoxic function is impaired in CLL-derived
Vg9Vd2-T cells
The capacity of CLL cells to activate Vg9Vd2-T cells was de-
termined by measuring the expression of CD25 after coculture.
HC-derived Vg9Vd2-T cells were activated by CLL cells, as
demonstrated by robust induction of CD25 expression. In
contrast, culture with allogeneic healthy B cells did not alter
CD25 expression (Figure 1A-B).
The cytotoxic potency of Vg9Vd2-T cells against CLL was studied
by measuring target cell death after coculture of sorted HC
Vg9Vd2-T cells with CLL cells. The Burkitt lymphoma cell line
Daudi was used as a positive control target (supplemental
Figure 1A). Vg9Vd2-T cells from HCs induced CLL cell death
(Figure 1C). Cell death was granzyme dependent because pre-
treatment of Vg9Vd2-T cells with concanamycin A, which prevents
granule exocytosis, abrogated target cell death (Figure 1D).
Similarly, the cytotoxicity of CLL-derived Vg9Vd2-T cells toward
allogeneic CLL cells was measured. Vg9Vd2-T cells from CLL
patients were significantly less effective at inducing cell death in
CLL and Daudi target cells (Figure 1E).
To assess whether the impaired cytotoxicity of CLL-derived
Vg9Vd2-T cells reflects diminished activation, expression of
Table 1. Patient characteristics
Immunophenotype Cytokine assay Cytotoxicity assay Ex vivo activation
HCs
No. 20 12 5 4
Males, % 45 58 60 50
Age, mean (range), y 72 (53-84) 67 (53-79) 68 (62-73) 67 (62-73)
Vg9Vd2, mean (range), % of CD3 1.4 (0.1-4.9) 1.5 (0.1-4.9) 1.2 (0.5-1.5) 1.2 (0.5-1.5)
CMV1, % 55 50 40 50
CLL patients
No. 39 14 5 8
Males, % 67 50 60 50
Age, mean (range), y 64 (41-87) 67 (55-83) 64 (57-69) 64.9 (57-69)
Vg9Vd2, mean (range), % of CD3 1.0 (0.1-6.2) 0.8 (0.1-1.8) 1.3 (0.6-2.6) 1.2 (0.6-2.6)
CMV1, % 64.3 50 60 62.5
ALC, mean (range), 3109 cells/L 80.4 (15.3-358.7) 77.4 (19.8-226.1) 51.3 (28.0-95.6) 44.3 (10.6-95.6)
U-CLL, % 43.6 42.9 40 50
Rai stage 011, % 72 64 60 62.5
ALC, absolute leukocyte count.
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the activation marker CD69 was measured after coculture with
Daudi cells. V9Vd2-T cells from CLL patients were activated by
the Daudi cells but not as strongly as were the HC Vg9Vd2-T
cells (Figure 1F).
Taken together, these results indicate activation of Vg9Vd2-
T cells by CLL, resulting in a granzyme-dependent cytotoxic
response. However, cytotoxic function is impaired in Vg9Vd2-
T cells from CLL patients, suggesting phenotypic and functional
alterations of Vg9Vd2-T cells in the context of CLL.
CLL-derived Vg9Vd2-T cells aremore differentiated
and express less granzyme B
A phenotypical analysis of CLL-derived vs HC-Vg9Vd2-T cells
was performed directly ex vivo. The absolute number as well as
the proportion of Vg9Vd2-T cells was comparable in CLL patients
and age-matched HCs (Figure 2A-B). Vg9Vd2-T cells can be
divided into naive, central memory, effector memory (EM), and
RA re-expressing effector memory (EMRA) subsets based on the
surface expression of CD27 and CD45RA.38-40 Functionally, central
memory and naive cells have a larger proliferative response,
whereas EM and EMRA cells have a higher cytokine production
and cytotoxic capacity. CLL-derived Vg9Vd2-T–cell subsets were
skewed, with a higher prevalence of EM cells, at the expense of
naive-type cells (Figure 2C; supplemental Figure 1B-C). In CD81
T cells fromCLL patients, subset distribution is skewed, particularly in
CMV1 patients.15 The subset distribution of Vg9Vd2-T cells was
similar in CMV1 and CMV2CLL patients (supplemental Figure 1D-E).
Similar to ab T cells, the expression of exhaustion markers
correlates with dysfunction in Vg9Vd2-T cells.41,42 Therefore,
expression of PD-1, BTLA, CD160, CD244, and LAG-3 was
determined (Figure 2D). Of these markers, only CD160 ex-
pression was higher on CLL Vg9Vd2-T cells compared with HC
Vg9Vd2-T cells. There were no significant differences between
CMV1 and CMV2 patients with regard to the expression of
exhaustion markers (supplemental Figure 1D-E).
To obtain mechanistic insight into the impaired cytotoxic
function of CLL-derived Vg9Vd2-T cells, the cytotoxic effector


















































































































Figure 1. Vg9Vd2-T–cell recognition and lysis of CLL cells. (A) Representative plot of geometric mean fluorescence intensity (gMFI) of CD25 expression measured after a
36-hour coculture of HC Vg9Vd2-T cells with CLL cells (solid red line), allogeneic healthy B cells (dashed blue line), or Vg9Vd2-T cells alone (light green shading). (B) As in (A),
scatter plot summarizing results for 6 donors. (C-E) Cell death of carboxyfluorescein succinimidyl ester–labeled target cells after overnight coculture with Vg9Vd2-T cells,
measured by MitoTracker Orange and TO-PRO-3. (C) Specific lysis of CLL cells after coculture with Vg9Vd2-T cells from HCs at the indicated effector-to-target ratios (n 5 9).
Specific lysis was calculated as (% cell death in stimulated cells)2 % cell death in unstimulated cells)/(% viable cells in unstimulated cells) * 100. (D) Healthy Vg9Vd2-T cells were
treated for 2 hours with 100 nM concanamycin A (CMA) or dimethyl sulfoxide and washed before coculture with CLL cells at a 1:1 ratio (n5 9). (E) Specific lysis of allogeneic CLL
and Daudi cells after coculture with Vg9Vd2-T cells from CLL patients (n5 6) or HCs (n5 9) at a 1:1 ratio. (F) CD69 expression on Vg9Vd2-T cells from CLL patients (n5 8) or HCs
(n5 4) after overnight coculture with Daudi cells at a 1:5 ratio. Data are mean and SEM. *P, .05, **P, .01, ***P, .001, ****P, .0001, 1-way ANOVA, followed by the Dunnett
(B) or Bonferroni (E-F) correction; paired t test (D).
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Vg9Vd2-T cells. CLL-derived Vg9Vd2-T cells contained less gran-
zyme B than HC-derived Vg9Vd2-T cells. In contrast, the per-
centage of Vg9Vd2-T cells expressing granzyme K did not differ
between HCs and CLL patients (Figure 2E).
The function of Vg9Vd2-T cells can be attenuated through
natural killer cell receptors; in particular, NKG2D promotes ef-
fector functions.43 The functional impairments observed in
Vg9Vd2-T cells from CLL patients do not merely reflect lower
NKG2D expression levels, which were, in fact, somewhat higher
on CLL Vg9Vd2-T cells (supplemental Figure 1G).
Diminished effector-type cytokine production and
cytotoxic potential of CLL-derived Vg9Vd2-T cells
Next, functional differences in cytokine production between HC
and CLL Vg9Vd2-T cells were determined. Upon TCR-independent
stimulation with PMA/ionomycin, Vg9Vd2-T cells from HCs
andCLL patients producedmainly effector-type cytokines (IFN-g
and TNF-a) (Figure 3A). Significantly fewer CLL Vg9Vd2-T cells
produced IFN-g (30.0% vs 51.4%) and TNF-a (30.0% vs 55.2%)
compared with their healthy counterparts. Because IFN-g and
TNF-a production was diminished, the possibility of T helper 2
(TH2) skewing was analyzed. Vg9Vd2-T cells from CLL patients
produced as much IL-4 as HCs (Figure 3A).
Recently, a tumor-promoting role has been attributed to IL-
17–producing gd T cells in solid malignancies.44 The percentage
of IL-17–producing Vg9Vd2-T cells was negligible in HCs and
CLL patients following PMA/ionomycin stimulation (Figure 3A).
Cytokine production upon contact with malignant B cells was
then measured in Vg9Vd2-T cells. Coculture with Daudi cells
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Figure 2. Frequency and immune phenotype of Vg9Vd2-T cells in CLL patients and HCs. Immunophenotyping of Vg9Vd2-T cells from untreated CLL patients and age-
matched HCs, directly ex vivo. (A) Frequency of Vg91Vd21 cells within CD31 T lymphocytes (CLL, n 5 39; HC, n 5 20). (B) Absolute number of Vg9Vd2-T cells (CLL, n 5 39; HC,
n5 6). (C) Distribution of differentiation subsets within Vg9Vd2-T cells based on CD27 and CD45RA expression (CLL, n5 39; HC, n5 20). (D) Expression of exhaustion markers
on Vg9Vd2-T cells. Geometric mean fluorescence intensity (gMFI) of PD-1 and BTLA expression (CLL, n5 39; HC, n5 20) and CD244, CD160, and LAG-3 expression (CLL, n5 16;
HC, n 5 11). (E) Frequency of granzyme B1 and granzyme K1 cells within Vg9Vd2-T cells (CLL, n 5 7; HC, n 5 7). Data are mean and SEM. *P , .05, Student t test. TCM, CD271
CD45RA2; TEM, CD272CD45RA2; TEMRA, CD272CD45RA1; TN, CD271CD45RA1.
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TNF-a production was significantly impaired in CLL Vg9Vd2-
T cells compared with HC Vg9Vd2-T cells.
Moreover, expression of CD107a, a marker for degranulation,
was significantly lower in Vg9Vd2-T cells from CLL patients in
response to PMA/ionomycin (Figure 3C), as well as CLL cells
(Figure 3D).
In summary, the production of IFN-g and TNF-a, as well as
degranulation in response to TCR-independent stimulation and
malignant B cells, is diminished in CLL Vg9Vd2-T cells, resulting
in a diminished TH1 response and cytotoxic capability.
CLL cells can induce dysfunction in healthy Vg9Vd2-
T cells
We hypothesized that functional impairments in Vg9Vd2-T cells
result from CLL-related immune suppression rather than an in-
trinsic Vg9Vd2-T–cell defect. This was supported by the obser-
vation that cytotoxicity (supplemental Figure 2A), effector-type
cytokine production (supplemental Figure 2B), and degranulation
(supplemental Figure 2C) correlated inversely with absolute leu-
kocyte count. The cytotoxic capacity, degranulation, and effector-
type cytokine production of Vg9Vd2-T cells from U-CLL patients
and patients with CLL with mutated immunoglobulin genes was
comparable (supplemental Figure 2D-F).
To test whether CLL cells could induce functional impairments in
healthy Vg9Vd2-T cells, HC Vg9Vd2-T cells were cultured for 48
hours in the presence of CLL cells or allogeneic healthy B cells.
After subsequent coculture with Daudi cells as targets, Vg9Vd2-
T cells that were cocultured with CLL cells produced significantly
less IFN-g and TNF-a than did Vg9Vd2-T cells that were cocultured
with healthy B cells or medium alone (Figure 4A). Similarly, degran-
ulation was impaired in CLL-cocultured Vg9Vd2-T cells (Figure 4B).
Production of effector-type cytokines (Figure 4C) and degranu-
lation (Figure 4D) were also impaired upon TCR-independent
stimulation with PMA/ionomycin in healthy Vg9Vd2-T cells that
were cocultured with CLL cells. IL-4 production was not affected
by CLL coculture.
In conclusion, CLL cells can induce dysfunction in healthy
Vg9Vd2-T cells.
ABP pretreatment of CLL cells modestly
augments cytotoxicity
Because ABP treatment can increase target cell recognition by
Vg9Vd2-T cells through upregulation of phosphoantigen lev-
els,18 and ABPs were previously shown to increase phos-
phoantigen production by CLL cells,31 we examined whether
ABP treatment of target cells could overcome the observed
dysfunction in CLL-derived Vg9Vd2-T cells.
First, we confirmed the expression of CD277/BTN3A1, the
transmembrane protein required for phosphoantigen recogni-
tion,18 on CLL cells (supplemental Figure 3A-B). Pretreatment of
Daudi cells with ABPs led to more IFN-g–producing Vg9Vd2-
T cells and lysis of Daudi cells (supplemental Figure 3C-F). In
contrast, ABP pretreatment of CLL cells generated only a trend
toward increased IFN-g and TNF-a production by CLL-derived
Vg9Vd2-T cells (supplemental Figure 3C-D), yet it did enhance
degranulation (supplemental Figure 3E). Correspondingly, CLL-
derived Vg9Vd2-T cells lysed allogeneic CLL cells more effi-
ciently after ABP treatment (supplemental Figure 3F), although
not to the level of HC Vg9Vd2-T cells (Figure 1E).
Thus, ABP pretreatment of CLL cells has a modest sensitizing
effect on lysis by Vg9Vd2-T cells in the context of dysfunctional
Vg9Vd2-T cells from CLL patients.
Vg9Vd2-T–cell dysfunction is reversible upon ex
vivo activation
To examine the plasticity of Vg9Vd2-T–cell dysfunction and the




























































































Figure 3. Impaired production of effector cytokines and degranulation in CLL-
derived Vg9Vd2-T cells. (A) Production of IFN-g, TNF-a, IL-17 (CLL, n5 14; HC, n5
12), and IL-4 (CLL and HC, n 5 4) by Vg9Vd2-T cells after stimulation with PMA/
ionomycin for 4 hours. (B) CD19-depleted PBMCs from CLL patients (n 5 8) or HCs
(n 5 8) were cocultured with allogeneic CLL cells or Daudi cells for 16 to 18 hours.
During the last 6 hours of coculture, brefeldin A andGolgiStopwere added tomeasure
cytokine production in Vg9Vd2-T cells. (C) CD107a expression in Vg9Vd2-T cells after
PMA/ionomycin stimulation for 4 hours (CLL, n 5 14; HC, n 5 12). (D) CD107a ex-
pression after coculture with malignant B cells as in (B). Data are mean and SEM. *P,
.05, 1-way ANOVA, followed by the Bonferroni post hoc test (A), Student t test (B-D).
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Vg9Vd2-T cells from HCs or CLL patients were activated ex vivo
by culturing them for 2 weeks with phosphoantigen-expressing
HC-derived moDCs in the presence of IL-7 and IL-15.35 Samples
from patients with a previously confirmed dysfunctional phe-
notype (Figures 1E and 3) were used.
Following ex vivo culture, cytokine production and degranulation
upon coculturewithDaudi cellsweremeasured. Thepercentageof
Vg9Vd2-T cells that produced IFN-g, TNF-a, or IL-4 did not differ
between CLL- and HC-derived cultured Vg9Vd2-T cells (supple-
mental Figure 4A), which was also true with regard to degranu-
lation (supplemental Figure 4B). Furthermore, cultured Vg9Vd2-T
cells from HCs and CLL patients killed an equal amount of Daudi
cells (supplemental Figure 4C). Thus, Vg9Vd2-T–cell dysfunction
in CLL patients is fully reversible upon ex vivo activation.
To adapt this activation method to a clinically achievable setting,
the reversibility of the dysfunction was subsequently tested using
autologous moDCs and serum. The proliferative capacity of
Vg9Vd2-T cells was similar with allogeneic and autologousmoDCs
(mean expansion factor 87.00 6 16.46 vs 76.42 6 8.55) and was
not impaired in CLL-derived Vg9Vd2-T cells in comparison with
HC-derived Vg9Vd2-T cells (Figure 5A). Vg9Vd2-T cells from CLL
patients and HCs were equally activated after culture, as measured
by CD25 expression (supplemental Figure 4D).
After autologousmoDCactivation, thenumber of cells that produced
IFN-g, TNF-a, or IL-4 in response to Daudi cells was equivalent in
CLL- and HC-derived Vg9Vd2-T cells (Figure 5B). Moreover, the
reductions in degranulating CLL-derived Vg9Vd2-T cells
(Figure 5C) and lysis of Daudi cells (supplemental Figure 4C)
were no longer observed after autologous moDC activation. In
line with this, granzyme B levels in Vg9Vd2-T cells increased
during ex vivo activation and did not differ between HC- and
CLL-derived Vg9Vd2-T cells (Figure 5D). To assess the long-
term potential of expanded Vg9Vd2-T cells, the differentiation
status after ex vivo activation was assessed. The Vg9Vd2-T cells
were primarily differentiated toward a memory phenotype after
moDC activation (Figure 5E). Moreover, there was a trend
toward diminished CD160 expression on HC- and CLL-derived
Vg9Vd2-T cells after ex vivo activation (Figure 5F).
Because the generation of moDCs complicates this ex vivo ac-
tivation method, an expansion protocol based on previous clinical
trials was also tested.28,30,45,46 In short, PBMCs were depleted,
using magnetic bead depletion, from B cells and CLL cells and
subsequently cultured in the presence of ABPs and IL-2 for 2
weeks. Using this protocol, we could generate functional Vg9Vd2-
T cells from HCs and CLL patients (supplemental Figure 4). Yet,
the expansion of the Vg9Vd2-T cells was inferior in comparison
with the moDC-based protocol (Figure 5A).
In conclusion, ex vivo expansion of CLL-derived Vg9Vd2-T cells
using a clinically feasible activation method resulted in fully
functional Vg9Vd2-T cells with a memory phenotype.
The transcriptional profile of Vg9Vd2-T cells from
CLL patients is globally altered
To gain more mechanistic insight into the observed differ-
ences between Vg9Vd2-T cells from HCs and CLL patients
before activation, we performed RNA sequencing analyses on
Vg9Vd2-T cells directly after thawing and after autologous
moDC-based activation.
Although there was considerable interdonor variation, as could
























































































Figure 4. CLL cells induce Vg9Vd2-T–cell dysfunction.Cytokine
production (A) and CD107a expression (B) by HC Vg9Vd2-T cells
after coculture with allogeneic healthy B cells or CLL cells for
36 hours at a 1:10 ratio and subsequent coculture with ABP-
pretreated Daudi cells (n 5 6). Cytokine production (C) and
CD107a expression (D) by HC Vg9Vd2-T cells after coculture and
subsequent stimulation with PMA/ionomycin (n 5 6). Data are
mean and SEM. *P , .05, **P , .01, ***P , .001, ****P , .0001,
1-way ANOVA, followed by the Bonferroni post hoc test.
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analysis showed that Vg9Vd2-T cells from CLL patients cluster
apart from Vg9Vd2-T cells from HCs (Figure 6A). Ex vivo activation
had a strong effect on the transcriptional profile of the Vg9Vd2-
T cells, and Vg9Vd2-T cells from CLL patients and HCs clustered
together after ex vivo activation. Thus, transcriptomics fitted with
the previously observed altered function of Vg9Vd2-T cells from
CLL patients in comparison with HC Vg9Vd2-T cells, which was no
longer the case after ex vivo activation.
Increased expression of 83 genes was observed in CLL Vg9Vd2-
T cells in comparison with HC Vg9Vd2-T cells prior to expansion
(Figure 6B). The expression of considerably more genes (n5 430)
was decreased in these CLL Vg9Vd2-T cells. In line with principal
component analysis, no genes were differentially expressed be-
tween CLL and HC Vg9Vd2-T cells after ex vivo activation.
We hypothesized that the most relevant candidate gene sets un-
derlyingour functional observationswouldbedifferentially expressed
between CLL and HC Vg9Vd2-T cells before ex vivo activation but
comparably expressed after ex vivo activation (Figure 6C). Gene
set enrichment analysis indicated that the concerned gene sets
were primarily immune related and included TNF-a signaling via
NF-kB and adhesion and diapedesis of lymphocytes.
Next, we compared the expression levels of selected genes
hypothesized to be most relevant to Vg9Vd2-T–cell function
(supplemental Table 2) between Vg9Vd2-T cells from CLL pa-
tients and HCs. Although the statistical power was limited, these
data point to differential expression of genes that relate to T-cell
memory, inhibition and exhaustion, costimulation, and synapse
formation and adhesion (Figure 6D). Although genes involved in
costimulation and memory were differentially expressed by CLL
Vg9Vd2-T cells before activation, the same differences persisted
after ex vivo activation (supplemental Figure 5A-C), making these
unlikely candidates to explain our functional observations.We then
zoomed in on genes related to synapse formation and adhesion,
most of which were downregulated in CLL Vg9Vd2-T cells com-
pared with HC Vg9Vd2-T cells before ex vivo activation (Figure 6E)
but not after ex vivo activation (supplemental Figure 5F). Although
there were some exceptions, genes attributed to T-cell inhibition
and exhaustion were generally upregulated in CLL Vg9Vd2-T cells,

































































































































Figure 5. Vg9Vd2-T–cell dysfunction is reversible upon ex vivo activation and expansion. Vg9Vd2-T cells from CLL patients (n 5 8), with previously confirmed impaired
function, and Vg9Vd2-T cells from HCs (n5 4) were sorted by FACS and subsequently cultured for 2 weeks with phosphoantigen-expressing moDCs in the presence of IL-7 and
IL-15. Alternatively, Vg9Vd2-T cells (CLL, n 5 4; HC, n 5 4) were generated from CD19-depleted PBMCs by culture in the presence of ABPs and IL-2 for 2 weeks. (A) Expansion
factor of Vg9Vd2-T cells calculated by dividing the amount of Vg9Vd2-T cells after a 2-week culture with allogeneic HC-derivedmoDCs (Allo-moDC) or autologousmoDCs (Auto-
moDC) by the number of Vg9Vd2-T cells at the start of culture. Cytokine production (B) and CD107a expression (C) by CLL-derived and HC-derived Vg9Vd2-T cells after culture
with autologousmoDCs. Vg9Vd2-T cells were cocultured with ABP-pretreatedDaudi cells for 16 to 18 hours, and brefeldin A andGolgiStop were added during the last 6 hours of
coculture. Granzyme B (D) and CD160 (F) expression on Vg9Vd2-T cells before and after culture with autologousmoDCs. (E) Distribution of differentiation subsets within Vg9Vd2-
T cells after culture with autologous moDCs based on CD27 and CD45RA expression. Data are mean and SEM. **P, .01, paired t test (D,F). TCM, CD271CD45RA2; TEM, CD272
CD45RA2; TEMRA, CD272CD45RA1; TN, CD271CD45RA1.
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Figure 6. Altered Vg9Vd2-T–cell transcriptional profile in CLL patients. RNA sequencing was performed on paired Vg9Vd2-T cells from 4 CLL patients and 4 HCs, directly
after thawing and after autologousmoDC-based expansion. (A)Multidimensional scaling plot of gene-expression data. Each circle represents an individual donor. (B) Number of
genes differentially expressed (false discovery rate, 0.05) in the indicated comparisons. (C) Gene set enrichment analysis of CLL vs HC Vg9Vd2-T cells, before (x-axis) and after
(y-axis) ex vivo expansion. Each circle represents a gene set [derived from the Hallmark (H) or BioCarta (B) gene sets from the Molecular Signatures Database or self-generated
gene sets]. Gene sets differentially expressed (P, .01) before, but not after (P. .1), expansion are highlighted in orange and purple. (D) Gene set enrichment analysis of CLL vs
HC Vg9Vd2-T cells directly prior to ex vivo expansion. The red dashed line indicates P5 .05. Also shown is whether each gene set is up- or downregulated in CLL in comparison
with HC Vg9Vd2-T cells. (E-F) The gene expression of CLL Vg9Vd2-T cells was compared with HC Vg9Vd2-T cells. Each circle represents an individual gene. Genes related to
synapse and adhesion (E) or inhibitory and exhaustion (F) molecules are highlighted in red. Genes with a P value,.05 and/or a fold change#21.75 or$1.75 are annotated. FC,
fold change; NK, natural killer cell.
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Thus, RNA sequencing confirmed that Vg9Vd2-T cells from
CLL patients have a transcriptional profile that is distinct fromHC
Vg9Vd2-T cells and implicated impaired synapse formation and
increased inhibitory molecules as conceivable contributors to
compromised Vg9Vd2-T–cell function in CLL patients.
Ibrutinib promotes TH1 skewing of Vg9Vd2-T cells
The BTK inhibitor ibrutinib not only targets malignant B cells,
it also skews ab T cells toward a tumor-suppressive TH1
phenotype through inhibition of ITK.47 Whether ITK is
expressed and exerts a similar role in Vg9Vd2-T cells has not
been studied.
CLL-derived Vg9Vd2-T cells that were pretreated with ibrutinib
produced significantly more TNF-a upon coculture with ABP-
treated Daudi cells (Figure 7A). In contrast, IL-4–producing
Vg9Vd2-T–cell numbers declined after ibrutinib treatment.
Ibrutinib treatment did not impair the degranulation of
Vg9Vd2-T cells (Figure 7B). To study whether effects of ibrutinib
indeed depended on inhibition of targets other than BTK,
Vg9Vd2-T cells from CLL patients were pretreated with the highly
BTK-specific inhibitor CC-292.48 In contrast to ibrutinib, CC-292
did not alter cytokine production by Vg9Vd2-T cells (Figure 7C).
To test whether ITK was bound by ibrutinib in Vg9Vd2-T cells, we
performed competitive pull-down experiments utilizing bio-
tinylated ibrutinib coupled to avidin-agarose. Specific binding of
BTK to biotinylated ibrutinib was confirmed in the CLL-derived
Mec-1 cell line, which could be reverted by ibrutinib or CC-292
pretreatment (Figure 7D). ITK was bound by biotinylated ibru-
tinib in Vg9Vd2-T cells. Pretreatment with ibrutinib, but not with
CC-292, blocked ITK binding.
Taken together, these experiments demonstrate that ibrutinib,
but not CC-292, promotes a TH1 phenotype in Vg9Vd2-T cells
from CLL patients that is likely mediated by ITK inhibition.
Discussion
Vg9Vd2-T cells are attractive effector cells for immunotherapy that
are capable of major histocompatibility complex–independent
recognition ofmalignant cells. In linewith the cytotoxic capacity of
Vg9Vd2-T cells toward other malignant B cells,18,21-24 we dem-
onstrate Vg9Vd2-T–cell cytotoxicity toward CLL cells.
However, clinical application of autologous Vg9Vd2-T cells
seems hampered by the observed dysfunction in Vg9Vd2-T cells.
Indeed, CLL cells have been found to have an active immuno-
suppressive function.49,50 In agreement with these findings, we
show here that CLL cells also induce dysfunction in healthy
donor–derived Vg9Vd2-T cells. Although the expression of ex-
haustion markers, especially PD-1, correlates with ab T-cell
dysfunction in CLL,13 Vg9Vd2-T cells do not express increased



















































































Figure 7. Ibrutinib promotes TH1 phenotype in Vg9Vd2-T cells. (A-B) CD19-depleted PBMCs were treated with 0, 10, or 100 nM ibrutinib for 30 minutes and subsequently
cocultured with ABP-pretreated (25 mM pamidronate for 2 hours) Daudi cells. During the last 6 hours of coculture, brefeldin A and GolgiStop were added to measure cytokine
production (A) andCD107a expression (B) in Vg9Vd2-T cells (n5 10). (C) Cytokine production as in (A) after pretreatment with 0, 10, or 100 nMCC-292 (n5 6). Data aremean and SEM.
(D) Pull-down with biotinylated ibrutinib coupled to avidin agarose; uncoupled avidin agarose was used as a control. Lysates from healthy Vg9Vd2-T cells or controlMec-1 B cells were
treated with 1 mM ibrutinib or 1 mM CC-292 before pull-down. Representative result of 3 donors in 2 independent experiments is shown. *P , .05, 1-way ANOVA, followed by the
Dunnett post hoc test.
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CD160 expression was upregulated on Vg9Vd2-T cells from CLL
patients, and genes related to T-cell exhaustion were generally
expressed at higher transcriptional levels in CLL Vg9Vd2-T cells.
Although the functional role of CD160 in gd T cells has only been
described in the context of CD3 stimulation,51 it is plausible that
CD160 has an inhibitory role in Vg9Vd2-T cells, as was described in
ab T cells.52 Gene-expression profiling also implicated alterations in
synapse formation in the observed cytotoxic impairment, as has
been demonstrated for ab T cells in CLL.14 Vg9Vd2-T–cell anergy
can arise as a result of chronic phosphoantigen overstimulation.53,54
A similar mechanism in CLL is supported by our observation that
naiveVg9Vd2-T cells are lost, anddysfunction increaseswithdisease
stage, as well as that Vg9Vd2-T–cell numbers were increased in
advanced-stage CLL in comparison with monoclonal B-cell lym-
phocytosis and Rai stage 0 disease.55 The possibility of chronic
overstimulation of Vg9Vd2-T cells as the result of a hyperactive
mevalonate pathway in U-CLL cells was proposed previously.31
We explored several approaches to improve the function of CLL-
derived Vg9Vd2-T cells. Pharmacological enhancement of
phosphoantigen levels is clinically feasible, and in vivo induction
of Vg9Vd2-T–cell proliferation using administration of ABPs or
synthetic phosphoantigens and IL-2 has been achieved in
solid25-27 and lymphoid24 malignancies. However, ABP treatment
only led to amodest lysis-sensitizing effect of primary CLL cells in
vitro, which might be explained by overactivity of the mevalo-
nate pathway in CLL.
Next, we examined ex vivo activation of Vg9Vd2-T cells in light of
adoptive-transfer strategies. Clinical trials have demonstrated
safety28-30 and efficacy30,45,56,57 of ex vivo–expanded Vg9Vd2-T–cell
administration. In line with our data, other investigators have shown
that sufficient Vg9Vd2-T–cell numbers can be achieved by ex-
pansion using coculture with moDCs,58 as well as through adding
synthetic phosphoantigens or ABPs to PBMCs.56 Moreover, we
demonstrate that it is possible to generate Vg9Vd2-T cells with
regained functionality in an autologous ex vivo culture system that
is clinically feasible. The function of Vg9Vd2-T cells improved for all
patients tested, although the number of patients tested was lim-
ited. Activation with moDCs was performed in the presence of IL-
15, which was previously shown to be superior to IL-2 for induction
of sustained proliferation, TH1 skewing, and degranulation.46,59
Most Vg9Vd2-T cells had a memory phenotype after ex vivo ac-
tivation, which is favorable in light of long-term functionality.60-62
Finally, we investigated combination strategies with novel BTK
inhibitors, which allow for selective elimination of CLL cells while
largely sparing T cells. In fact, ibrutinib has been shown to increase
T-cell numbers and reduce the immunosuppressive features of
CLL,63,64 conceivably favoring subsequent autologous T-cell ther-
apy. Specifically, ibrutinib promotes a favorable antitumor TH1
profile in Vg9Vd2-T cells derived from CLL patients, similar to what
was previously shown for CD41 T cells.47,63 Because TH1 skewing
did not occur with CC-292, the effect is likely mediated by in-
hibition of ITK, aswas supportedbyour pull-downexperiments.48,65
Hence, ibrutinib may be a suitable candidate to combine with
autologous Vg9Vd2-T-cell–based therapy.
In conclusion, Vg9Vd2-T cells are cytotoxic toward CLL cells, and
dysfunction of autologous Vg9Vd2-T cells is fully reversible upon
ex vivo expansion. Because autologous Vg9Vd2-T cells can be
expanded to high numbers, and ibrutinib stimulates an antitu-
mor TH1 pattern, further exploration of combining Vg9Vd2-T–cell
adoptive transfer with ibrutinib treatment is justified.
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